Wealth Enhancement Advisory Services
VRTX icon

Wealth Enhancement Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
45,889
+5,221
+13% +$2.31M 0.04% 416
2026
Q1 		$17.4M Sell
40,668
-40,578
-50% -$18.9M 0.04% 434
2025
Q4 		$38.1M Buy
81,246
+7,777
+11% +$3.35M 0.05% 313
2025
Q3 		$30.1M Sell
73,469
-9,172
-11% -$3.83M 0.05% 340
2025
Q2 		$38M Buy
82,641
+2,452
+3% +$1.13M 0.06% 275
2025
Q1 		$38.9M Hold
80,189
– – 0.07% 249
2024
Q4 		$32.3M Sell
80,189
-21,702
-21% -$10.1M 0.06% 281
2024
Q3 		$47.4M Buy
101,891
+16,279
+19% +$7.82M 0.1% 197
2024
Q2 		$40.1M Buy
85,612
+3,576
+4% +$1.55M 0.1% 208
2024
Q1 		$34.3M Buy
82,036
+7,061
+9% +$2.98M 0.09% 220
2023
Q4 		$30.5M Buy
74,975
+27,386
+58% +$10.1M 0.09% 213
2023
Q3 		$16.5M Buy
47,589
+37,677
+380% +$13.2M 0.05% 314
2023
Q2 		$3.49M Buy
9,912
+134
+1% +$45.1K 0.04% 154
2023
Q1 		$3.08M Buy
9,778
+84
+0.9% +$25.2K 0.04% 168
2022
Q4 		$3.1M Sell
9,694
-3,525
-27% -$1.07M 0.04% 149
2022
Q3 		$3.9M Buy
+13,219
New +$3.8M 0.06% 131
2022
Q2 		– Sell
-22,874
Closed -$6.15M – 372
2022
Q1 		$6.15M Buy
22,874
+831
+4% +$197K 0.08% 119
2021
Q4 		$5.37M Buy
+22,043
New +$4.29M 0.08% 117
2020
Q4 		– Sell
-6,920
Closed -$1.9M – 250
2020
Q3 		$1.9M Sell
6,920
-5,547
-44% -$1.53M 0.05% 120
2020
Q2 		$3.63M Buy
+12,467
New +$3.38M 0.1% 72
2019
Q1 		– Sell
-7,325
Closed -$1.43M – 223
2018
Q4 		$1.43M Buy
+7,325
New +$1.27M 0.09% 84
2017
Q4 		– Sell
-5,716
Closed -$887K – 173
2017
Q3 		$887K Sell
5,716
-1,193
-17% -$180K 0.07% 119
2017
Q2 		$893K Buy
+6,909
New +$832K 0.08% 109

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Wealth Enhancement Advisory Services's VRTX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $2.31M and bringing the position to 45,889 shares worth $21.5M. The position accounts for 0.04% of the portfolio, ranked #416.

Wealth Enhancement Advisory Services first reported a position in VRTX in Q2 2017 and has held it in 23 quarters since. The position peaked at $47.4M in Q3 2024. 280 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 45,889 shares of Vertex Pharmaceuticals worth $21.5M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 5,221 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.31M.
  • Vertex Pharmaceuticals made up 0.04% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #416 holding.
  • Wealth Enhancement Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 23 quarters since.
  • Wealth Enhancement Advisory Services's Vertex Pharmaceuticals position peaked at $47.4M in Q3 2024.
  • 280 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.